{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:34:08Z","timestamp":1788053648498,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jchf.2024.11.011","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T14:04:38Z","timestamp":1738591478000},"page":"346-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Costabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edileide","family":"de Barros Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Dybro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K.","family":"Lakdawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajith","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Nassif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen H.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Reant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Christian","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrias","family":"Berhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Heitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady I.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wohltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Fifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.jchf.2024.11.011_bib1","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.jchf.2024.11.011_bib2","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Writing Committee Members","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jchf.2024.11.011_bib3","first-page":"221","article-title":"Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis","volume":"106","author":"Brock","year":"1957","journal-title":"Guys Hosp Rep"},{"issue":"5","key":"10.1016\/j.jchf.2024.11.011_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.CIR.35.5.847","article-title":"Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade","volume":"35","author":"Cohen","year":"1967","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jchf.2024.11.011_bib5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/hrt.32.6.804","article-title":"Long-term propranolol therapy in muscular subaortic stenosis","volume":"32","author":"Adelman","year":"1970","journal-title":"Br Heart J"},{"issue":"3","key":"10.1016\/j.jchf.2024.11.011_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCULATIONAHA.107.694158","article-title":"Management of symptoms in hypertrophic cardiomyopathy","volume":"117","author":"Fifer","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jchf.2024.11.011_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0002-9149(81)90086-2","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration","volume":"48","author":"Rosing","year":"1981","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.jchf.2024.11.011_bib8","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A\u00a0double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jchf.2024.11.011_bib9","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jchf.2024.11.011_bib10","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10253","key":"10.1016\/j.jchf.2024.11.011_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jchf.2024.11.011_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jchf.2024.11.011_bib13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jchf.2024.11.011_bib14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jamacardio.2022.5099","article-title":"Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial","volume":"8","author":"Wheeler","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.jchf.2024.11.011_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","article-title":"A\u00a0phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants","volume":"7","author":"Malik","year":"2022","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10.1016\/j.jchf.2024.11.011_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.11.011_bib17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","article-title":"Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4","volume":"30","author":"Masri","year":"2024","journal-title":"J\u00a0Card Fail"},{"issue":"11","key":"10.1016\/j.jchf.2024.11.011_bib18","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cardfail.2023.07.003","article-title":"Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving disopyramide: REDWOOD-HCM cohort 3","volume":"29","author":"Owens","year":"2023","journal-title":"J\u00a0Card Fail"},{"issue":"19","key":"10.1016\/j.jchf.2024.11.011_bib19","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jchf.2024.11.011_bib20","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jacc.2024.09.002","article-title":"Standard of care medication withdrawal in patients with obstructive hypertrophic cardiomyopathy receiving aficamten in FOREST-HCM","volume":"84","author":"Masri","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"suppl_2","key":"10.1016\/j.jchf.2024.11.011_bib21","article-title":"Changes in standard of care (SOC) medication during long-term mavacamten treatment for obstructive hypertrophic cardiomyopathy (HCM): results from the EXPLORER cohort of MAVA-long-term extension (LTE)","volume":"44","author":"Lakdawala","year":"2023","journal-title":"Eur Heart J"},{"issue":"47","key":"10.1016\/j.jchf.2024.11.011_bib22","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jchf.2024.11.011_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jchf.2023.10.004","article-title":"Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design","volume":"12","author":"Coats","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"20","key":"10.1016\/j.jchf.2024.11.011_bib24","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jchf.2024.11.011_bib25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924008746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924008746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T12:35:33Z","timestamp":1740659733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924008746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2213177924008746"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.11.011","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}